Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
4(50%)
Results Posted
50%(1 trials)
Terminated
2(25%)

Phase Distribution

Ph phase_1
7
88%
Ph phase_2
1
13%

Phase Distribution

7

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
7(87.5%)
Phase 2Efficacy & side effects
1(12.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

4

trials recruiting

Total Trials

8

all time

Status Distribution
Active(4)
Completed(2)
Terminated(2)

Detailed Status

Active, not recruiting2
Terminated2
Recruiting2
Completed2

Development Timeline

Analytics

Development Status

Total Trials
8
Active
4
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 17 (87.5%)
Phase 21 (12.5%)

Trials by Status

active_not_recruiting225%
terminated225%
recruiting225%
completed225%

Recent Activity

4 active trials
Showing 5 of 8
active_not_recruitingphase_1

Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

NCT05349890
active_not_recruitingphase_1

Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

NCT04520711
recruitingphase_1

A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

NCT05849480
recruitingphase_1

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

NCT05029999
terminatedphase_2

Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients

NCT04536077
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT05349890Phase 1

Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

Active Not Recruiting
NCT04520711Phase 1

Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

Active Not Recruiting
NCT05849480Phase 1

A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

Recruiting
NCT05029999Phase 1

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

Recruiting
NCT04536077Phase 2

Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients

Terminated
NCT04364230Phase 1

Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)

Completed
NCT05484011Phase 1

A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Terminated
NCT03329950Phase 1

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8